Cargando…
S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428383/ http://dx.doi.org/10.1097/01.HS9.0000968124.64352.6e |
| _version_ | 1785090455897112576 |
|---|---|
| author | Kenet, Gili Nolan, Beatrice Zulfikar, Bulent Antmen, Bulent Kampmann, Peter Matsushita, Tadashi You, Chur-Woo Vilchevska, Kateryna Bag, Catherine N. Sharif, Azizan Peyvandi, Flora Young, Guy Negrier, Claude Sussebach, Christian Shammas, Fadi Andersson, Shauna Mei, Baisong Kavakli, Kaan |
| author_facet | Kenet, Gili Nolan, Beatrice Zulfikar, Bulent Antmen, Bulent Kampmann, Peter Matsushita, Tadashi You, Chur-Woo Vilchevska, Kateryna Bag, Catherine N. Sharif, Azizan Peyvandi, Flora Young, Guy Negrier, Claude Sussebach, Christian Shammas, Fadi Andersson, Shauna Mei, Baisong Kavakli, Kaan |
| author_sort | Kenet, Gili |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428383 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104283832023-08-17 S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS Kenet, Gili Nolan, Beatrice Zulfikar, Bulent Antmen, Bulent Kampmann, Peter Matsushita, Tadashi You, Chur-Woo Vilchevska, Kateryna Bag, Catherine N. Sharif, Azizan Peyvandi, Flora Young, Guy Negrier, Claude Sussebach, Christian Shammas, Fadi Andersson, Shauna Mei, Baisong Kavakli, Kaan Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428383/ http://dx.doi.org/10.1097/01.HS9.0000968124.64352.6e Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Kenet, Gili Nolan, Beatrice Zulfikar, Bulent Antmen, Bulent Kampmann, Peter Matsushita, Tadashi You, Chur-Woo Vilchevska, Kateryna Bag, Catherine N. Sharif, Azizan Peyvandi, Flora Young, Guy Negrier, Claude Sussebach, Christian Shammas, Fadi Andersson, Shauna Mei, Baisong Kavakli, Kaan S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS |
| title | S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS |
| title_full | S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS |
| title_fullStr | S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS |
| title_full_unstemmed | S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS |
| title_short | S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS |
| title_sort | s303: a phase 3 study (atlas-ppx) to evaluate efficacy and safety of fitusiran in people with haemophilia a or b who have switched from prior clotting factor concentrate or bypassing agent prophylaxis |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428383/ http://dx.doi.org/10.1097/01.HS9.0000968124.64352.6e |
| work_keys_str_mv | AT kenetgili s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT nolanbeatrice s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT zulfikarbulent s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT antmenbulent s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT kampmannpeter s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT matsushitatadashi s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT youchurwoo s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT vilchevskakateryna s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT bagcatherinen s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT sharifazizan s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT peyvandiflora s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT youngguy s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT negrierclaude s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT sussebachchristian s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT shammasfadi s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT anderssonshauna s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT meibaisong s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis AT kavaklikaan s303aphase3studyatlasppxtoevaluateefficacyandsafetyoffitusiraninpeoplewithhaemophiliaaorbwhohaveswitchedfrompriorclottingfactorconcentrateorbypassingagentprophylaxis |